Ernexa Therapeutics (ERNAW) Enterprise Value (2010 - 2026)

Ernexa Therapeutics has reported Enterprise Value for 17 years, with the latest figure at -$9.2 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 378.47% year-over-year to -$9.2 million; the trailing twelve-month figure through Mar 2026 stood at -$9.2 million (down 378.47% YoY), and the FY2025 full-year result was -$1.9 million, down 8.96% from the prior year.
• Enterprise Value for Q1 2026 stood at -$9.2 million, down from -$1.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$1.7 million in Q4 2024, with the low at -$23.5 million in Q1 2022.
• Historically, Enterprise Value has averaged -$10.2 million across 5 years, with a median of -$10.0 million in 2023.
• Annual changes were most pronounced in 2024 — Enterprise Value surged 89.03% — and 2026, when it tumbled 378.47%.
• Ernexa Therapeutics' Enterprise Value stood at -$19.6 million in 2022, then grew by 19.71% to -$15.8 million in 2023, then surged by 89.03% to -$1.7 million in 2024, then fell by 8.96% to -$1.9 million in 2025, then slumped by 387.1% to -$9.2 million in 2026.
• The last three Enterprise Value figures came in at -$9.2 million (Q1 2026), -$1.9 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.